[Potential pharmacological treatments for diabetic retinopathy].
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine.
Daisuke
D
Watanabe
Hitoshi
H
Takagi
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000975:Antioxidants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors*; D013006:Growth Hormone / Q000037:antagonists & inhibitors; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D048289:Imidazolidines / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D008301:Maleimides / Q000494:pharmacology / Q000627:therapeutic use*; D015282:Octreotide / Q000627:therapeutic use*; D010102:Oxygen Inhalation Therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000627:therapeutic use; D013831:Thiamine / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology
D000975:Antioxidants; D016861:Cyclooxygenase Inhibitors; D017127:Glycation End Products, Advanced; D006146:Guanidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D048289:Imidazolidines; D007211:Indoles; D008301:Maleimides; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; C116890:Semaxinib; C099154:ruboxistaurin; D013006:Growth Hormone; D000449:Aldehyde Reductase; D011493:Protein Kinase C; C026411:sorbinil; D015282:Octreotide; C004479:pimagedine; D013831:Thiamine